We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. DENVER — Primary generalized tonic-clonic seizures ...

The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...

Credit: Shutterstock. Eprontia is approved for the treatment of partial-onset or primary generalized tonic-clonic seizures and migraine prevention. The Food and Drug Administration (FDA) has approved ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

BOSTON — Preliminary results from a meta-analysis have shown that antiepileptic drugs (AEDs) approved for adults with primary generalized tonic-clonic (PGTC) seizures are also effective in children ...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with ...

Perampanel was found effective and safe for prolonged use in children with epilepsy, according to one study. After its 2012 approval as an antiseizure medication, perampanel (Fycompa) has been found ...

A seizure is a sudden change in the brain's normal electrical activity. During a seizure, brain cells "fire" uncontrollably at up to four times their normal rate, temporarily affecting the way a ...

Children exposed prenatally to antiseizure medications were at greater risk of autism spectrum disorders (ASD) and intellectual disability (ID), according to a population-based cohort study. By ...

NASHVILLE, Tennessee ―The retention rate for the antiseizure drug perampanel (Eisai Co, Ltd) is more than 70% for adult patients with epilepsy, new research shows. In early results from the PERPRISE ...

VNS Therapy has not been approved by the U.S. Food and Drug Administration (FDA) for use in primary generalized seizures, and the safety and effectiveness of VNS Therapy for the reduction of primary ...